<h4>Objective</h4>To summarize the clinical experience of a patient with advanced non-small cell lung cancer (NSCLC) who achieved long-term survival after treatment with the programmed cell death protein 1 (PD-1) inhibitor nivolumab.<h4>Methods</h4>We retrospectively analyzed the case of a 78-year-old male patient diagnosed in April 2018 with right lung adenocarcinoma (cT4N3M1a, stage IV). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.